Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.

PloS one - 1 Jan 2013

Johnson Daniel H, Sutherland Deborah, Acosta Edward P, Erdem Husamettin, Richardson Danielle, Haas David W

Abstract excerpt

BACKGROUND: Antiretroviral drugs vary in their central nervous system penetration, with better penetration possibly conferring neurocognitive benefit during human immunodeficiency virus (HIV) therapy. The efflux transporter gene ABCB1 is expressed in the blood-brain barrier, and an ABCB1 variant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood-Brain Barrier

Share to Homozygote

Share to Permeability

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Open in PubMed Open full text

Identifiers

PMID: 24349334
DOI: 10.1371/journal.pone.0082672
PMCID: PMC3859605

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-24349334-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.PMID 24349334Read ↗

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.Semantic proximity Read ↗

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.Semantic proximity Read ↗

Pharmacogenetics and the Blood-Brain Barrier: A Whirlwind Tour of Potential Clinical UtilitySemantic proximity Read ↗

Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV.Semantic proximity Read ↗

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single‐dose efavirenz population pharmacokinetics in UgandansSemantic proximity Read ↗

Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants.Semantic proximity Read ↗

Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations.Semantic proximity Read ↗

Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency VirusSemantic proximity Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.